Table 3.

Outcomes of etomidate vs. control stratified by hydrocortisone use

	Etomidate (n = 23)			Control (n = 39)
	Hydrocortisone	Placebo	P-Value	Hydrocortisone	Placebo	P-value
	N = 14	N = 9		N = 20	N = 19
ICU mortality, No.%	12 (85.7)	9 (100)	0.50	12 (60)	13 (68.4)	0.74
Hospital mortality, No.%	14 (100)	9 (100)		18 (90)	19 (100)	0.49
28-day mortality, No.%	13 (92.9)	8 (88.9)	1.0	18 (90)	15 (79)	0.41
Delta norepinephrine (d2-1) (μ/kg/min)	-0.05 ± 0.23	0.15 ± 0.36	0.05	-0.10 ± 0.24	0.08 ± 0.25	0.02
Delta norepinephrine (d3-1) (μ/kg/min)	-0.10 ± 0.26	0.31 ± 0.36	0.01	-0.20 ± 0.33	0.06 ± 0.28	0.02
ICU length of stay (days), mean ± SD	13.7 ± 7.2	10.9 ± 8.5	0.23	9.4 ± 5.9	9.3 ± 5.6	0.93
Ventilation-free days, mean ± SD	3.6 ± 5.6	0.2 ± 0.4	0.04	6.2 ± 6.6	5.8 ± 8.5	0.6
Vasopressor-free days, mean ± SD	4.6 ± 6.9	1.1 ± 3.3	0.05	7.1 ± 8.0	3.8 ± 7.5	0.20